ESAS was initially developed by Bruera and colleagues as a clinical tool to document the symptom burden in patients with advanced cancer admitted to a palliative care unit.

This topic discusses the indications, efficacy, and risks associated with the erythropoiesis-stimulating agents (ESAs) in anemic patients with nonhematologic malignancies, including epoetin alfa, darbepoetin alfa, and biosimilars.

Symptom Assessment System (ESAS). Although there are many cancer symptom assessment tools [15], the ESAS continues to dominate the symptom assessment field in advanced cancer and palliative care. It is brief, comprehensive and practical; relevant to palliative care; and entails minimum patient burden, which is particularly important for

Erythropoiesis-stimulating agents (ESAs) are widely used in the management of anemia in cancer patients. Despite their apparent effectiveness, recent studies have suggested that ESAs could result in serious adverse events and even higher mortality.

Erythropoiesis-stimulating agents (ESAs) have been implicated in causing cancer progression. This belief has been largely based on trials in the early 2000s of ESA use in malignancy with high hemoglobin (Hgb) targets and large ESA doses to attain the targets.

To compare the time duration of self‐completion (SC) of the Edmonton Symptom Assessment Scale (ESAS) by patients with advanced cancer (ACPs) versus assisted completion (AC) with a health care professional.

Jul 2, 2024 · ESAS-r Cancer is now in use with patients throughout CCA. This valid and reliable PRO measure can be used by other cancer or specialized health care programs who wish to routinely assess common symptoms.

Apr 10, 2019 · Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin (HgB) levels and reduces the need for RBC transfusions, but increases the risk of thromboembolic events. 1,2 Studies have also reported decreased survival, increased mortality during active study phase, and/or an increased risk of cancer progression or recurrence ...

The Edmonton symptom assessment scale (ESAS) in cancer and palliative care patients: Systematic Literature review Year 2011 Pages 30 The ESAS is a brief and clinically useful bedside tool for self-reporting symptom intensity by advanced cancer and palliative care patients.

Feb 24, 2023 · Currently, there are no guidelines for nephrologists regarding erythropoietin stimulating agents (ESAs or Epo or Darbe) use in patients with CKD with previous or active malignancy. Recently an excellent review of this topic was published in Kidney International by Hazzan et al. Let’s go over some of the key points.